New hope for deadly parasitic disease as experimental drug enters testing
NCT ID NCT05593666
Summary
This study is testing a new oral drug called LXE408 for treating visceral leishmaniasis, a serious parasitic infection. It will compare two different dosing schedules of LXE408 against the current standard treatment (AmBisome) in about 101 patients aged 12 and older. The main goal is to see if the new drug safely clears the infection and prevents it from coming back within six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
DrugsNeglectedD Investigational Site
Bihār, India
-
DrugsNeglectedD Investigational Site
Patna, India
Conditions
Explore the condition pages connected to this study.